Ryan Sullivan

Harvard University
Country flagUnited States
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (27)

Background Prior studies in patients with BRAF ‐mutant melanoma have shown increased density of tumor infiltrating lymphocytes (TIL) after 2 weeks of BRAF (BRAFi) ± MEK inhibition (MEKi), but did not characterize the functional state or clonal diversity of TIL over time. We evaluated sequential tumor biopsies during therapy to test the hypotheses that BRAF/MEKi would increase TIL to day 29, with increases in IFNγ signatures and T‐cell homing receptor ligands and expansion of functional intratumoral tumor‐reactive CD8 T‐cells and TIL clonality in the tumor microenvironment. Methods Subjects with biopsy‐accessible BRAF ‐mutant advanced melanoma received vemurafenib+/−cobimetinib. Tumor biopsies were obtained at baseline and days 8, 15, and 29 on therapy. Tumors were analyzed by quantitative immunofluorescence (QIF), NanoString, and TCRseq. Results Five patients were enrolled. All had an initial tumor response followed by subsequent progression. In four patients, both CD8 + and CD4 + TIL density increased by day 8 or 15 per QIF and continued to increase at day 29 in two. Gene expression data showed upregulation of genes/pathways associated with immunologic rejection of cancer, including Class I and II MHC expression, antigen processing/presentation, and critical T‐cell attracting chemokines. TCRvβ clonal expansion was observed in 3 patients, but most diminished after day 15. Conclusions Data from this study provides provocative evidence that, while BRAF+/−MEK inhibitor therapy produces an increase in overall and clonal T cell infiltrates, there is limited evidence for generation of new or persistent tumor immunity. Thus, BRAFi/MEKi therapy may enable tumor‐reactive T cells to infiltrate tumors but tumor control does not appear to depend on priming new immune responses.

Year:

2026

Background Immune checkpoint inhibitors (ICIs) have revolutionized melanoma treatment, with programmed cell death protein 1 (PD-1) inhibitors—alone or in combination with cytotoxic T-lymphocyte–associated protein 4 or lymphocyte-activation gene 3 inhibitors—demonstrating significant efficacy. However, there is a critical lack of robust data to determine the optimal sequencing of these therapies for individual patients. In particular, the role of relatlimab+nivolumab (rela/nivo) within treatment sequences remains poorly defined. Choosing the right sequence is strategic, as an inappropriate order may compromise the effectiveness of subsequent treatments and limit long-term benefits. Methods This multicenter retrospective and prospective study evaluated 190 patients across three treatment arms: rela/nivo followed by ipilimumab+nivolumab (ipi/nivo) (arm A, N=40), ipi/nivo followed by rela/nivo (arm B, N=71), and anti-PD-1 followed by rela/nivo (arm C, N=79). The study assessed the impact of treatment sequencing on outcomes including response rate, progression-free survival, and overall survival (OS). Results The overall response rate to second treatment was highest in arm C (30.4%), followed by arm B (28.1%) and arm A (17.5%). Patients with secondary resistance to first-treatment ICIs had better responses to second-treatment ICIs than those with primary resistance, particularly in arm B (p=0026). Median OS from date of first ICI treatment was significantly longer in arms B (40.9 months) and C (42.5 months) compared with arm A (16.3 months). Conclusions Our findings indicate that rela/nivo may remain active following anti-PD-1 or ipi/nivo therapy. Additionally, our results suggest that sequencing ipi/nivo before rela/nivo may yield better outcomes than starting with rela/nivo. Patients who respond to the first combination regimen appear to derive greater benefit from the second. Further efforts are needed to optimize sequencing strategies in advanced melanoma, and future studies should consider the impact of prior treatment outcomes.

Year:

2025

Purpose: We conducted an integrated safety analysis from three clinical studies of tebentafusp, a first-in-class ImmTAC bispecific T-cell engager, which can redirect T cells to target glycoprotein 100–positive cells, in metastatic uveal melanoma. Experimental Design: HLA-A*02:01–positive patients with unresectable or metastatic uveal melanoma enrolled in three clinical trials (IMCgp100-01, IMCgp100-102, and IMCgp100-202) who received ≥1 dose of tebentafusp were included. Safety data were pooled to evaluate the profile, onset, and management of treatment-related adverse events (TRAE). Adverse events of special interest included cytokine release syndrome (CRS), acute skin reactions (ASR), and liver function test elevations. Primary prophylaxis with medications was not permitted. Results: Among 410 tebentafusp-treated patients, the most common TRAE were pyrexia (77%), pruritus (71%), and chills (53%). Most patients experienced CRS (88%), almost always mild (grade 1, 19%) to moderate (grade 2, 67%) in severity, with only 2% experiencing grade 3 ( n = 6) or 4 ( n = 1) CRS. Additionally, 92% had at least one ASR, primarily pruritus and rash, with 21% having a grade 3 event. Onset of CRS and ASR was within 1 to 2 days of infusion and generally reversible with standard interventions. Elevated liver function tests were generally mild and resolved without intervention. Most TRAE occurred following the first few infusions and diminished in frequency and severity with repeated dosing; no cumulative TRAE were detected. Discontinuations due to TRAE were rare (2%); there were no treatment-related deaths. Conclusions: TRAE were consistent with tebentafusp’s mechanism of action, mostly occurred during dose escalation, and were predictable, reversible, and manageable with appropriate surveillance and intervention.

Year:

2025

Attenuation of select TRAE with repeated dosing. Incidence and severity of select TRAE over time for patients with mUM treated with tebentafusp across all studies ( N = 410). A, Weekly incidence of TRAE during the acute phase (1–12 weeks). B, Long-term incidence of TRAE in 3-month intervals up to 30 months, which can be broken down into acute (months 1–3), intermediate (months 4–12), and late phases (>12 months). *Rash, LFT, and MRAE are composite terms for a list of related AE of any grade (Supplementary Table S1).

Year:

2025

Frequency of AESI by maximum grade and kinetics of onset and resolution of AESI. A, Frequency of each AESI by grade. CRS was programmatically graded post hoc according to the ASTCT consensus grading criteria for CRS for patients in studies 102 and 202 ( N = 391). CTCAE grading for treatment-emergent ASR and elevations in LFT for all patients ( N = 410). B and C, Median time to ( A ) onset from the start of the first dose or ( B ) resolution from the start of AESI for CRS, ASR, and LFT elevations. The peak of each curve shows the proportion of patients who developed that AESI. CRS was programmatically graded post hoc according to the ASTCT consensus grading criteria for CRS for patients in studies 102 and 202 ( N = 391). CTCAE grading for treatment-emergent ASR and elevations in LFT for all patients ( N = 410).

Year:

2025

Landmark OS for corticosteroid use within the first 30 days of the first tebentafusp dose. Kaplan–Meier plot of inverse probability of treatment–weighted OS (ATE weights) by corticosteroid use within the first 30 days of the first tebentafusp dose, landmarked at day 30. HR (95% confidence interval), 1.09 (0.67–1.76). ATE, average treatment effects.

Year:

2025

Background Immune checkpoint inhibitors (ICIs) are associated with a 3‐fold risk of atherosclerotic cardiovascular disease (ASCVD). However, the biology of atherosclerosis is different among women and men, and ASCVD risk factors among women treated with an ICI are incompletely understood. This study aimed to identify factors associated with ASCVD in women following ICIs and to characterize plaque progression. Methods In a single‐center retrospective study, clinical and cancer‐related factors were compared among women treated with ICIs who did and did not experience ASCVD. Competing risk analysis estimated the effect of ICIs on cardiovascular risk. In an imaging substudy, the rate of atherosclerotic plaque progression post‐treatment was compared between women and men. Results Among 1188 female patients treated with an ICI, 54 (5%) experienced an ASCVD with a median time to event of 174 days. Patients with ASCVD had a higher prevalence of prior myocardial infarction and coronary revascularization (15% versus 6%, P =0.007) and prior stroke (7% versus 2%, P =0.039). Competing risk analyses, adjusting for cardiovascular risk factors, revealed an almost 3‐fold increased risk of post‐ICI ASCVD in women with prior cardiovascular events (hazard ratio, 2.71 [95% CI, 1.24–5.95]; P =0.013). In an imaging study, the annual rate of plaque progression post‐ICI was 6% for total and 7% for non‐calcified plaque, with similar rates of progression observed in women and men. Conclusions In female patients treated with ICIs, 5% developed an ASCVD, and a history of cardiovascular events was a risk factor. In an imaging study, plaque progressed in a short time frame after ICI therapy.

Year:

2025

Immune checkpoint inhibitors (ICIs) have improved survival of patients with cancer, yet they pose risks of immune-related adverse events (irAEs). ICI-induced insulin-dependent diabetes mellitus (ICI-DM) is a life-threatening and life-altering irAE. Previously, we reported a high incidence of a germline missense variant in NLRC5 , a key class I transcription activator, among patients with ICI-DM compared with similarly treated patients who did not develop ICI-DM. Our purpose was to validate this finding in additional ICI-treated patients and study effects of the NLRC5 variant on expression of class I major histocompatibility complex (MHC) antigen presentation genes. We assessed the prevalence of the C>T missense variant at chr16:57 025 515 ( NLRC5Pro191Leu ) in germline DNA from an additional 33 patients with ICI-DM and in patients with ICI-induced colitis (n=15), ICI-induced hypothyroidism (n=19) and ICI-induced hypophysitis (n=17). The 1,000 Genomes Project was used for comparison. We assessed peripheral blood mononuclear cells from 16 individuals with or without the NLRC5 variant, studying expression of NLRC5 and select downstream target genes, before and after stimulation with interferon-γ. We validated the higher prevalence of NLRC5Pro191Leu in a non-overlapping cohort of patients with ICI-DM compared with the general population (51.5% vs 12.8%, p<0.0001). The prevalence of NLRC5Pro191Leu in ICI-induced colitis or thyroiditis patients did not significantly differ from the general population, while the prevalence in ICI-induced hypophysitis was somewhat higher (21.6%, p=0.048). We found greater increases in messenger RNA expression of NLRC5 (p=0.007), TAP1 (p=0.0002), B2M (p=0.0005), HLA-G (p=0.04), PSMB8 (p=0.03) and PSMB9 (p=0.01) in NLRC5Pro191Leu cells stimulated with interferon-γ compared with NLRC5 WT cells. A similar trend was observed for HLA-A (p=0.09). We confirm the significantly higher prevalence of the NLRC5Pro191Leu variant in patients with ICI-DM relative to the general population. This abundance appears to be unique to patients who develop ICI-DM or hypophysitis on ICIs, underscoring its potential involvement in the pathogenesis of these endocrinopathies. The effects of this NLRC5 variant on class I MHC regulators suggest a mechanistic connection between the variant and development of ICI-DM. Further work is warranted to determine whether class I MHC molecules can be modulated in patients with the NLRC5Pro191Leu variant requiring ICIs.

Year:

2025

PURPOSE Immunotherapy has improved survival for patients with melanoma and non–small cell lung cancer (NSCLC). Yet, as responses vary widely, immunotherapy also introduces challenges in prognostic communication. In this study, we sought to explore how patients and caregivers learned about the goal of immunotherapy and their experience of living with uncertainty. MATERIALS AND METHODS We conducted a qualitative study of patients with stage III or IV melanoma or stage IV NSCLC within 12 weeks of initiating or 12 months of discontinuing immunotherapy, and their caregivers. We conducted in-depth interviews with participants to explore how they learned about immunotherapy from oncology clinicians and how they experienced uncertainty. We used a framework approach to analyze interview transcripts and synthesized concepts into themes. RESULTS Forty-two patients and 10 caregivers participated; median age was 67 years and most were male (68%), white (95%), married (61%), and had melanoma (62%). We identified four themes: (1) the oncology team shaped participants' hopeful expectations of immunotherapy, including as a potential cure among those with melanoma; (2) distress related to prognostic uncertainty particularly affected patients who experienced toxicity or progressive disease; (3) patients who did not have long-term responses experienced overwhelming disappointment; and (4) some patients and caregivers had conflicting preferences for prognostic information. Participants provided suggestions to improve education and underscored unmet psychosocial needs. CONCLUSION Patients and caregivers held optimistic expectations of immunotherapy, which resulted in heightened disappointment among the subset with progression or toxicity. Clinicians should elicit information preferences of both patients and caregivers, as these may be disparate. Our results highlight the need to optimize prognostic communication and support for living with uncertainty among patients receiving immunotherapy.

Year:

2025

Purpose: Eganelisib (IPI-549) is a first-in-class, orally administered, highly selective PI3Kγ inhibitor with antitumor activity alone and in combination with programmed cell death protein 1/ligand 1 (PD-1/PD-L1) inhibitors in preclinical studies. This phase 1/1b first-in-human, MAcrophage Reprogramming in Immuno-Oncology-1 (NCT02637531) study evaluated the safety and tolerability of once-daily eganelisib as monotherapy and in combination with nivolumab in patients with solid tumors. Patients and Methods: Dose-escalation cohorts received eganelisib 10–60 mg as monotherapy ( n = 39) and 20–40 mg when combined with nivolumab ( n = 180). Primary endpoints included incidence of dose-limiting toxicities (DLT) and adverse events (AE). Results: The most common treatment-related grade ≥3 toxicities with monotherapy were increased alanine aminotransferase (ALT; 18%), aspartate aminotransferase (AST; 18%), and alkaline phosphatase (5%). No DLTs occurred in the first 28 days; however, toxicities meeting DLT criteria (mostly grade 3 reversible hepatic enzyme elevations) occurred with eganelisib 60 mg in later treatment cycles. In combination, the most common treatment-related grade ≥3 toxicities were increased AST (13%) and increased ALT and rash (10%). Treatment-related serious AEs occurred in 5% of monotherapy patients (grade 4 bilirubin and hepatic enzyme increases in one patient each) and 13% in combination (pyrexia, rash, cytokine release syndrome, and infusion-related reaction in ≥2 patients each). Antitumor activity was observed in combination, including patients who had progressed on PD-1/PD-L1 inhibitors. Conclusions: On the basis of the observed safety profile, eganelisib doses of 30 and 40 mg once daily in combination with PD-1/PD-L1 inhibitors were chosen for phase 2 study.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (50)

caroline robert

- Directeur de l’équipe «Résistance thérapeutique» dans l’Unité INSERM U 981 : Biomarqueurs prédicteurs et nouvelles stratégies moléculaires en thérapeutique anticancéreuse

Université de Paris Faculté de Santé

FRANCE
View details

Joan Brugge

Professor

Harvard University

UNITED STATES
View details

Govind Warrier

Assistant Professor of Oncology

Johns Hopkins University

UNITED STATES
View details

Lara Traeger

Associate Professor

University of Miami

UNITED STATES
View details

Georgina V. Long

University of Sydney

AUSTRALIA
View details

Joseph J. Sacco

Senior Lecturer Clinical

University of Liverpool

UNITED KINGDOM
View details

Khanh Do

Assistant Professor of Medicine

Dana-Farber Cancer Institute

UNITED STATES
View details

Jessica C. Hassel

Heidelberg University

GERMANY
View details

Takami Sato

Professor

Thomas Jefferson University

UNITED STATES
View details

Nora Zizlsperger

-

UNITED STATES
View details

Daniel Zlotoff

Harvard University

UNITED STATES
View details

Viktor Adalsteinsson

Group Leader

Broad Institute

UNITED STATES
View details

Reinhard Dummer

University Hospital of Zurich

SWITZERLAND
View details

Alexander M. Menzies

University of Sydney

AUSTRALIA
View details

Christine Lian

Dermatopathologist/Associate Professor

Brigham and Women's Hospital

UNITED STATES
View details

Bartosz Chmielowski

Ronald Reagan UCLA Medical Center

UNITED STATES
View details

Marcus Butler

University Health Network

CANADA
View details

Harriet Kluger

Yale University School of Medicine

UNITED STATES
View details

John Kirkwood

Distinguished Service Professor of Medicine

University of Pittsburgh

UNITED STATES
View details

Allison Betof Warner

Assistant Professor, Director of Melanoma Medical Oncology, Director of Solid Tumor Cellular Therapy

Stanford University

UNITED STATES
View details

Ezra Cohen

Professor of Medicine

Moores Cancer Center, UC San Diego Health

UNITED STATES
View details

Elizabeth Buchbinder

Harvard University

UNITED STATES
View details

Béla Merkely

Semmelweis University

HUNGARY
View details

Genevieve Boland

Chair of Surgery

Medical College of Wisconsin

UNITED STATES
View details

Anthony M. Joshua

Head of Department

University Health Network

CANADA
View details

Michael A. Postow

Weill Cornell Medical College

UNITED STATES
View details

F. Dimitriou

Attending Physician, Head of Skin Cancer Center

University Hospital of Bern

SWITZERLAND
View details

Alexandra Ikeguchi

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Jeffrey Clark

Associate Professor

Harvard University

UNITED STATES
View details

Alexander Noor Shoushtari

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Paul Nathan

University College London

UNITED KINGDOM
View details

Jennifer A. Wargo

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Elizabeth Burton

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

David S. Hong

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Isabella C Glitza Oliva

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Sebastian Ochsenreither

Charité - Universitätsmedizin Berlin

GERMANY
View details

Christine Spencer

Parker Institute for Cancer Immunotherapy

UNITED STATES
View details

David Liu

Assistant Professor

Dana-Farber Cancer Institute

UNITED STATES
View details

Thuy Tran

Assistant Professor

Yale University Yale Cancer Center

UNITED STATES
View details

Zoltán V Varga

junior group leader

Semmelweis University

HUNGARY
View details

Jedd Wolchok

Director

Weill Cornell Medicine

UNITED STATES
View details

Piotr Rutkowski

Narodowy Instytut Onkologii im Marii Skłodowskiej-Curie Państwowy Instytut Badawczy w Warszawie

POLAND
View details

Mark Middleton

University of Oxford

UNITED KINGDOM
View details

Julie Densmore

Parker Institute for Cancer Immunotherapy

UNITED STATES
View details

Christine Peterson

Associate Professor

Rice University

UNITED STATES
View details

Paolo Antonio Ascierto

Full Professor

Università degli Studi di Napoli Federico II

ITALY
View details

Colin Weekes

Associate Professor

Massachusetts General Hospital

UNITED STATES
View details

Nadim Ajami

Executive Director

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Jennifer Temel

Massachusetts General Hospital

UNITED STATES
View details

Ines Pires da Silva

Medical Oncologist

University of Sydney

AUSTRALIA
View details